Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue
+2,356.5%
EPS
+46.3%
Free cash flow
−6.73%
Total debt
−83.9%

Quarter to September 2026, against a year earlier

54.93 0.62 −1.12%
Market cap
$7.7B
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a

Cytokinetics, Incorporated (CYTK) Net margin

Alert me on Net margin

Cytokinetics, Incorporated's net margin over the twelve months to 30 September 2026 was −686.6%, up 205.0 percentage points from fiscal 2025 (−891.6%). Over the past ten years it has ranged from −6,988.6% (fiscal 2023) to 15.5% (fiscal 2016); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −891.6% 2,299.51
FY2024 −3,191.1% 3,797.52
FY2023 −6,988.6% (6,577.42)
FY2022 −411.2% (105.49)
FY2021 −305.7% (77.72)
FY2020 −228.0% 224.93
FY2019 −452.9% (115.52)
FY2018 −337.4% 618.53
FY2017 −955.9% (971.40)
FY2016 15.5% 146.32

Quarterly newest first

Period Net margin Change (points)
Sep 2026 −399.7% 294.72
Jun 2026 −694.4% 370.09
Mar 2026 −1,064.5% (33.61)
Dec 2025 −1,030.9% 14,784.11
43 more quarters

Against its own ten years

Low −6,988.6% High 15.5%
Ten-year median −411.2%
Current reading's percentile 44

Net margin against peers

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on CYTK